738700login-checkTacrolimus After Lung Transplant Cuts Chronic Lung Allograft Dysfunction |
— Calcineurin inhibitor significantly reduced CLAD rates in Scandinavian trial
By Elizabeth Short
MILAN — Once-a-day tacrolimus significantly reduced chronic lung allograft dysfunction (CLAD) in lung transplant patients compared with the standard immunosuppressant, according to the ScanCLAD trial.
Among patients who underwent double lung transplantation, CLAD occurred significantly more often among those who received cyclosporine (cumulative incidence 39%, 95% CI 31-48) versus those who got tacrolimus (13%, 95% CI 8-21, P<0.0001) at 36 months post-procedure, reported Göran Dellgren, MD, PhD, of the University of Gothenburg, in Sweden, at the European Respiratory Societyopens in a new tab or window meeting. Read the article in MedPage Today.
738700login-checkTacrolimus After Lung Transplant Cuts Chronic Lung Allograft Dysfunction |